Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Alnylam's Fitusiran Could Provide Comprehensive Hemophilia Therapy Option

Aug 29 2016

• By Joseph Haas

Color of cells,Particles in liquid.

Related Content

Alnylam Advancing From Platform Buzz To Late-Stage Clinical Work

Dec 21 2015

Hemophilia Market Snapshot: Is There Enough Innovation For Patients To Switch?

Jun 30 2014

Biogen Hemophilia Spin Out Bioverativ On Track For Early 2017

Aug 09 2016

Shire Backs Hemophilia Focus With Asset Updates, Irish iPATH Study

Jul 27 2016

Related Companies

Alnylam Pharmaceuticals Inc.

Takeda Pharmaceutical Co. Ltd.

Biogen, Inc.

uniQure N.V.

Novo Nordisk A/S

Pfizer Inc.

Chugai Pharmaceutical Co., Ltd.

Roche Holding AG

Additional Topics

Clinical Trials Research & Development Companies Blood & Coagulation Disorders BioPharmaceutical

More from Blood and Clotting

More from Therapeutic Category

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window